Ganitumab

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Monkbot (talk | contribs) at 05:27, 1 October 2019 (→‎top: Task 16: replaced (2×) / removed (0×) deprecated |dead-url= and |deadurl= with |url-status=;). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Ganitumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetIGF-1R
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6472H10028N1728O2020S42
Molar mass145.7 kg/mol g·mol−1
 ☒NcheckY (what is this?)  (verify)

Ganitumab a human monoclonal antibody against type 1 insulin-like growth factor receptor (IGF1R), designed for the treatment of cancers.[1]

Ganitumab was developed by Amgen. A phase III clinical trial (for metastatic pancreatic cancer) was abandoned in August 2012.[2][3]

References

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ganitumab" (PDF). American MedicaAssociation.
  2. ^ "Amgen Pulls Cancer Drug". 10 Aug 2012. Archived from the original on 2013-07-23.
  3. ^ "Amgen (AMGN) Terminates Ganitumab Pancreatic Cancer Trial". 8 Aug 2012. Archived from the original on 2012-08-10.


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Ganitumab&oldid=918977897"